Why the study?
What patient, provider, and practice characteristics are associated with sacubitril/valsartan use in patients with HFrEF in the United States?
Population
4,216 patients with heart failure with reduced ejection fraction from 121 sites in the United States…
Comparison
Sacubitril/valsartan prescription vs ACE inhibitor/ARB prescription, or neither
Design
Cross-sectional
Authors
Loading...
Low sacubitril/valsartan adoption in HFrEF warrants caution; hypothesis-generating for advanced practice provider effects on uptake.
What patient, provider, and practice characteristics are associated with sacubitril/valsartan use in patients with HFrEF in the United States?
Adoption of sacubitril/valsartan in US HFrEF patients remains low at 15%, with use associated with younger age, fewer comorbidities, and larger practice sizes.
DeVore et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: